STOCK TITAN

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Spero Therapeutics schedules a webcast company presentation and one-on-one investor meetings at the September 2026 H.C. Wainwright conference.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Spero Therapeutics (SPRO)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 15, 2026, at 1:30 PM ET.President and CEO Esther Rajavelu will deliver the company presentation, and Spero's leadership team will be available for one-on-one meetings. The presentation will be webcast, with access via Spero's website Events + Presentations page and a replay available for about 90 days.

Loading...
Loading translation...

Key Figures

Conference edition: 28th annual Conference dates: September 14–16, 2026 Presentation date: September 15, 2026 +2 more
Conference edition
28th annual
H.C. Wainwright Global Investment Conference
Conference dates
September 14–16, 2026
H.C. Wainwright Global Healthcare Conference
Presentation date
September 15, 2026
Company presentation
Presentation time
1:30 PM ET
Company presentation
Replay availability
Approximately 90 days
Following the conference

Historical Context

5 past events · Latest: Aug 12
5 events
  1. Aug 12

    Second-quarter results

    24h Move
    +4.2%

    Utebzi approval, royalty financing, and extended operating runway supported the update

  2. Aug 05

    Inducement equity grant

    24h Move
    +0.8%

    New employee received stock options and restricted stock units under Nasdaq rules

  3. Aug 04

    Earnings date notice

    24h Move
    +2.4%

    Company scheduled second-quarter results and a business update for August 12

  4. Jul 27

    Leadership appointment

    24h Move
    -0.8%

    Debra Jeske Zack joined as chief medical officer to lead clinical development

  5. Jul 14

    Royalty financing

    24h Move
    -22.0%

    Non-dilutive financing and SP001 license expanded funding and pipeline access

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be held in New York City, September 14th -16th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

Presentation Details:

H.C. Wainwright 28th Annual Global Investment Conference
Company Presentation:September 15, 2026
Time:1:30 PM ET
Location:New York, NY
Webcast Link:Company Presentation
  

The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay of the webcast will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please reach out to your institutional contact at H.C. Wainwright.

About Spero Therapeutics

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com

Media Inquiries:
media@sperotx.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Spero Therapeutics (SPRO) present at the H.C. Wainwright 28th Annual Global Investment Conference?

Spero Therapeutics is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 1:30 PM ET in New York, NY. The company notes that its leadership team will also be available for one-on-one meetings during the event.

Where is the Spero Therapeutics (SPRO) presentation taking place during the H.C. Wainwright 2026 conference?

The Spero Therapeutics company presentation at the H.C. Wainwright 28th Annual Global Investment Conference will take place in New York, NY. The conference runs from September 14–16, 2026, with Spero's presentation scheduled for September 15 at 1:30 PM ET.

How can investors access the Spero Therapeutics (SPRO) webcast from the H.C. Wainwright 2026 conference?

The company presentation will be available via a webcast link and can also be accessed through Spero Therapeutics' website on the Events + Presentations page. A replay of the webcast will be available for approximately 90 days following the conference.

Will there be a replay of the Spero Therapeutics (SPRO) H.C. Wainwright 2026 conference presentation?

Yes. A replay of Spero Therapeutics' presentation at the H.C. Wainwright 28th Annual Global Investment Conference will be available for approximately 90 days after the conference. The replay can be accessed via the webcast and through the company's Events + Presentations webpage.

How can investors request a one-on-one meeting with Spero Therapeutics (SPRO) at the H.C. Wainwright 2026 conference?

To request a one-on-one meeting with Spero Therapeutics' leadership during the H.C. Wainwright 28th Annual Global Investment Conference, investors are directed to contact their institutional contact at H.C. Wainwright for scheduling and additional conference details.

Keep reading